Small molecule inhibitors of cyclin-dependent kinase 9 for cancer therapy
1Department of Pharmaceutical Sciences, College of Pharmacy, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia.
Journal of Enzyme Inhibition and Medicinal Chemistry
|February 26, 2021
Abstract:
Cyclin-dependent kinase 9 (CDK9) plays a vital role in transcription through regulation of short-lived anti-apoptotic genes required for cancer cell survival. Therefore, targeting CDK9 with small molecule inhibitors has emerged as a potential cancer therapy. This article reviews the most recent CDK9 patent literature (2012-2020) related to small molecule inhibitors in cancer along with their selectivity profile and biological results in preclinical studies.
Insights
Targeting cyclin-dependent kinase 9 (CDK9) with small molecule inhibitors shows promise for cancer therapy by disrupting cancer cell survival. This review covers recent CDK9 inhibitor patents and preclinical data.
Area of Science:
- Oncology
- Molecular Biology
- Medicinal Chemistry
Background:
- Cyclin-dependent kinase 9 (CDK9) is crucial for cancer cell survival by regulating anti-apoptotic genes.
- Targeting CDK9 presents a potential therapeutic strategy in cancer treatment.
- Small molecule inhibitors are being developed to target CDK9.
Purpose of the Study:
- To review recent patent literature (2012-2020) on small molecule inhibitors targeting CDK9 in cancer.
- To analyze the selectivity profiles of these inhibitors.
- To summarize their biological outcomes in preclinical cancer studies.
Main Methods:
- Systematic review of CDK9 inhibitor patent literature from 2012 to 2020.
- Analysis of inhibitor selectivity data.
- Compilation and summary of preclinical study results.
Main Results:
- Identified numerous small molecule inhibitors targeting CDK9 patented between 2012-2020.
- Evaluated the selectivity profiles of these compounds against various kinases.
- Summarized promising preclinical efficacy and biological activity data.
Conclusions:
- Recent patents demonstrate significant progress in developing selective CDK9 inhibitors for cancer.
- Preclinical data support the therapeutic potential of targeting CDK9 in various cancers.
- Further development of these inhibitors warrants investigation for clinical application.
Related Concept Videos
02:34Inhibition of Cdk Activity
5.3K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.3K
02:15M-Cdk Drives Transition Into Mitosis
6.0K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.0K
02:39Positive Regulator Molecules
6.1K
Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
6.1K
02:57Targeted Cancer Therapies
8.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.1K
02:50Combination Therapies and Personalized Medicine
5.6K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.6K
01:15Drugs that Stabilize Microtubules
2.3K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.3K